Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

women’s health strategy

- PMLiVE

Where next in Alzheimer’s disease R&D?

How past failures and emerging biology are reshaping drug development

- PMLiVE

Biogen and Eisai pull plug on Alzheimer’s drug

Further undermines amyloid-targeting approach

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

- PMLiVE

Lilly partners with AC Immune on tau drug for Alzheimer’s

Potential payments of $1.7bn to Swiss firm

- PMLiVE

Daily Brief: Dementia Fund hits $350m mark, hard Brexit could cost £100bn in trade and troublesome results for Pfizer’s Ibrance

The latest news from across pharma, biotech and healthcare

- PMLiVE

British Business Bank sets up £2.5bn fund for ‘unicorn’ firms

UK government says the private sector will bring in another £5bn in investments

- PMLiVE

Eisai to tackle dementia in new US research facility

Aims to introduce a new compound into the clinic by 2020

Celgene building

Celgene bulks up pipeline again with $2.1bn Prothena deal

Acquires candidates with potential in Alzheimer’s, ALS and dementia

- PMLiVE

Another Alzheimer’s bust as Merck & Co stops verubecestat study

Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai

Eisai launches location tracker for dementia patients

Collaborates with Japanese smartphone app network Mamorio on the new tool

- PMLiVE

IMI aims €130m at medical research’s unanswered questions

Targets for the partnership’s latest funding round including Alzheimer’s

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links